semaglutide patents Semaglutide's patent expires today. What does it mean for patients, pharma players and Novo Nordisk? Your Questions Answered: Off-patent Semaglutide

Understanding Semaglutide: How It Supports Your Goals Semaglutide is an FDA-approved GLP-1 receptor agonist designed for adults with obesity or overweight conditions

Alcohol You should avoid alcohol consumption while taking this medication as it can worsen drowsiness and dizziness

CrossRef Relationship Between Handgrip Strength and Laboratory Values in Adolescents With Non-Alcoholic Fatty Liver Disease Si Yeong Lee, Yong Whi Jeong, Hong Koh, Yunkoo Kang Journal of Clinical Densitometry.2022

And while not as prominent in the weight-loss space, Pfizer (NYSE: PFE) has recently doubled down on its efforts in that industry, signing a $2.1 billion licensing agreement in December 2025 with a Chinese pharmaceutical company to develop its early-stage weight-loss pill

For research workflows, the documentation is different: compound identity, supplier, COA or batch record, storage requirement, transport authorization if applicable, and the receiving location

Other Safety: Gallbladder disease: Rapid weight loss, from any cause, can precipitate gallstone formation